A Phase I, Open-label, Multicenter, Dose-escalation Study Evaluating the Safety, Tolerability, and Potential Efficacy of IBI325, an Anti-CD73 Antibody, in Patients With Advanced Solid Tumor
Latest Information Update: 22 Aug 2023
At a glance
- Drugs IBI 325 (Primary) ; Sintilimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Innovent Biologics
- 15 Aug 2023 Status changed from active, no longer recruiting to completed.
- 10 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2022 According to an Innovent media release, the first patient has been successfully dosed